The EBITDA margin of Solarvest BioEnergy, Inc. is -139,489.96%
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
Solarvest BioEnergy Inc. engages in the development of algal-based production systems to produce natural based green commercial products in Canada and internationally. The company provides human nutrition products, including omega-3; and pharmaceutical ingredients for human health comprising cannabinoids in algae and bone morphogenetic protein for the treatment of repairing bone fractures. It has a collaborative research and development agreement with FSD Pharma Inc. to develop algae-based pharmaceutical grade cannabinoids. The company was incorporated in 2005 and is based in Vancouver, Canada.